S&P 500   4,248.36 (+0.45%)
DOW   33,054.69 (+0.16%)
QQQ   358.62 (+1.04%)
AAPL   173.02 (+0.36%)
MSFT   318.10 (+1.50%)
META   304.79 (+1.28%)
GOOGL   134.93 (+1.89%)
AMZN   126.58 (+1.49%)
TSLA   257.63 (+4.50%)
NVDA   439.33 (+0.96%)
NIO   8.75 (+1.63%)
BABA   84.11 (-0.51%)
AMD   102.53 (+2.45%)
T   14.56 (-1.49%)
F   11.99 (-0.66%)
MU   67.90 (+0.10%)
CGC   0.75 (+9.59%)
GE   108.88 (+1.04%)
DIS   79.37 (-0.21%)
AMC   8.03 (+2.29%)
PFE   33.44 (-1.36%)
PYPL   58.15 (+1.48%)
NFLX   376.76 (+0.00%)
S&P 500   4,248.36 (+0.45%)
DOW   33,054.69 (+0.16%)
QQQ   358.62 (+1.04%)
AAPL   173.02 (+0.36%)
MSFT   318.10 (+1.50%)
META   304.79 (+1.28%)
GOOGL   134.93 (+1.89%)
AMZN   126.58 (+1.49%)
TSLA   257.63 (+4.50%)
NVDA   439.33 (+0.96%)
NIO   8.75 (+1.63%)
BABA   84.11 (-0.51%)
AMD   102.53 (+2.45%)
T   14.56 (-1.49%)
F   11.99 (-0.66%)
MU   67.90 (+0.10%)
CGC   0.75 (+9.59%)
GE   108.88 (+1.04%)
DIS   79.37 (-0.21%)
AMC   8.03 (+2.29%)
PFE   33.44 (-1.36%)
PYPL   58.15 (+1.48%)
NFLX   376.76 (+0.00%)
S&P 500   4,248.36 (+0.45%)
DOW   33,054.69 (+0.16%)
QQQ   358.62 (+1.04%)
AAPL   173.02 (+0.36%)
MSFT   318.10 (+1.50%)
META   304.79 (+1.28%)
GOOGL   134.93 (+1.89%)
AMZN   126.58 (+1.49%)
TSLA   257.63 (+4.50%)
NVDA   439.33 (+0.96%)
NIO   8.75 (+1.63%)
BABA   84.11 (-0.51%)
AMD   102.53 (+2.45%)
T   14.56 (-1.49%)
F   11.99 (-0.66%)
MU   67.90 (+0.10%)
CGC   0.75 (+9.59%)
GE   108.88 (+1.04%)
DIS   79.37 (-0.21%)
AMC   8.03 (+2.29%)
PFE   33.44 (-1.36%)
PYPL   58.15 (+1.48%)
NFLX   376.76 (+0.00%)
S&P 500   4,248.36 (+0.45%)
DOW   33,054.69 (+0.16%)
QQQ   358.62 (+1.04%)
AAPL   173.02 (+0.36%)
MSFT   318.10 (+1.50%)
META   304.79 (+1.28%)
GOOGL   134.93 (+1.89%)
AMZN   126.58 (+1.49%)
TSLA   257.63 (+4.50%)
NVDA   439.33 (+0.96%)
NIO   8.75 (+1.63%)
BABA   84.11 (-0.51%)
AMD   102.53 (+2.45%)
T   14.56 (-1.49%)
F   11.99 (-0.66%)
MU   67.90 (+0.10%)
CGC   0.75 (+9.59%)
GE   108.88 (+1.04%)
DIS   79.37 (-0.21%)
AMC   8.03 (+2.29%)
PFE   33.44 (-1.36%)
PYPL   58.15 (+1.48%)
NFLX   376.76 (+0.00%)
NASDAQ:AVTX

Avalo Therapeutics (AVTX) Stock Forecast, Price & News

$0.14
0.00 (-0.29%)
(As of 12:58 PM ET)
Compare
Today's Range
$0.13
▼
$0.14
50-Day Range
$0.08
▼
$0.23
52-Week Range
$0.08
▼
$7.00
Volume
43.54 million shs
Average Volume
18.61 million shs
Market Capitalization
$2.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Avalo Therapeutics MarketRank™ Forecast

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
7,379.4% Upside
$10.00 Price Target
Short Interest
Bearish
15.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.12) to ($4.62) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

See Top Rated MarketRank™ Stocks Here

AVTX stock logo

About Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

AVTX Price History

AVTX Stock News Headlines

September 27, 2023 | finance.yahoo.com
BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics
September 26, 2023 | benzinga.com
Why Avalo Therapeutics Stock Is Up Today
October 4, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
September 22, 2023 | benzinga.com
What's Going On With Avalo Therapeutics (AVTX) Stock?
September 18, 2023 | benzinga.com
Why Rubicon Technologies Shares Are Trading Lower By Over 7%; Here Are 20 Stocks Moving Premarket
September 13, 2023 | benzinga.com
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
September 13, 2023 | msn.com
Avalo drops three rare disease assets amid ongoing challenges
September 13, 2023 | benzinga.com
Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
October 4, 2023 | Behind the Markets (Ad)
"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
September 12, 2023 | marketwatch.com
Avalo Therapeutics Shares Rise 53% After Deal to Divest Certain Assets
September 12, 2023 | msn.com
Why Microcap Biotech Firm Avalo Therapeutics Stock Is Trading Higher Today?
September 12, 2023 | markets.businessinsider.com
Crude Oil Rises 2%; Avalo Therapeutics Shares Spike Higher
September 12, 2023 | markets.businessinsider.com
Avalo Therapeutics To Sell 800 Series Programs To AUG Therapeutics; Stock Surges
September 12, 2023 | seekingalpha.com
Avalo enters agreement to divest AVTX-800 series
September 12, 2023 | finance.yahoo.com
Avalo Enters into Agreement to Divest AVTX-800 Series
September 6, 2023 | finance.yahoo.com
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 22, 2023 | finance.yahoo.com
Is Avalo Therapeutics (AVTX) A Hidden Gem or A Value Trap?
August 3, 2023 | msn.com
Avalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue Estimates
August 3, 2023 | finance.yahoo.com
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
July 26, 2023 | benzinga.com
Avalo Therapeutics Stock (NASDAQ:AVTX) Insider Trades
July 6, 2023 | finance.yahoo.com
Avalo to Participate in SVB Securities Therapeutics Forum
June 28, 2023 | benzinga.com
Avalo Therapeutics 10% Owner Sold $1.03M In Company Stock
June 27, 2023 | msn.com
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
June 26, 2023 | msn.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.04%
June 26, 2023 | msn.com
Why Are Avalo Therapeutics Shares Plummeting On Monday
June 26, 2023 | msn.com
Avalo Plummets 80% on Phase 2 Disappointment in Asthma
June 26, 2023 | marketwatch.com
Avalo Therapeutics Shares Hit 52-Week Low After Trial Misses Primary Endpoint
See More Headlines
Receive AVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTX Company Calendar

Last Earnings
8/03/2023
Today
10/04/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVTX
CUSIP
N/A
CIK
1534120
Web
www.avalotx.com
Phone
(410) 522-8707
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+7,042.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-41,660,000.00
Net Margins
-146.01%
Pretax Margin
-145.84%
Return on Equity
N/A
Return on Assets
-75.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.33
Quick Ratio
0.33

Sales & Book Value

Annual Sales
$18.05 million
Price / Sales
0.16
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.16) per share
Price / Book
-0.12

Miscellaneous

Outstanding Shares
20,250,000
Free Float
11,056,000
Market Cap
$2.84 million
Optionable
Optionable
Beta
1.21
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Garry A. Neil M.D. (Age 69)
    Chairman, Pres & CEO
    Comp: $601.9k
  • Mr. Christopher Ryan SullivanMr. Christopher Ryan Sullivan (Age 39)
    CFO & Head of Investor relations
    Comp: $466.94k
  • Dr. Solomon H. Snyder M.D. (Age 84)
    Founder and Chairman of Scientific Advisory Board
  • Dr. Barbara S. Slusher Ph.D. (Age 58)
    Founder and Member of Scientific Advisory Board
  • Dr. Lisa Hegg Ph.D.
    Sr. VP of Program Management, Corp. Infrastructure & Clinical Operations
  • Ms. Colleen Matkowski
    Sr. VP of Global Regulatory Affairs & Quality Assurance
  • Dr. Dino C. Miano Ph.D.
    Sr. VP of CMC & Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AVTX Stock - Frequently Asked Questions

Should I buy or sell Avalo Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" AVTX shares.
View AVTX analyst ratings or view top-rated stocks.

What is Avalo Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued 12 month price targets for Avalo Therapeutics' shares. Their AVTX share price forecasts range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 7,042.9% from the stock's current price.
View analysts price targets for AVTX or view top-rated stocks among Wall Street analysts.

How have AVTX shares performed in 2023?

Avalo Therapeutics' stock was trading at $5.0401 at the beginning of 2023. Since then, AVTX stock has decreased by 97.2% and is now trading at $0.14.
View the best growth stocks for 2023 here.

Are investors shorting Avalo Therapeutics?

Avalo Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 3,070,000 shares, an increase of 220.1% from the August 31st total of 959,000 shares. Based on an average trading volume of 45,360,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 15.8% of the company's shares are short sold.
View Avalo Therapeutics' Short Interest.

When is Avalo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AVTX earnings forecast.

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.31. The business earned $0.64 million during the quarter, compared to analysts' expectations of $1 million.

When did Avalo Therapeutics' stock split?

Avalo Therapeutics's stock reverse split on Friday, July 8th 2022. The 1-12 reverse split was announced on Friday, July 8th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 8th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Avalo Therapeutics' stock symbol?

Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX."

How do I buy shares of Avalo Therapeutics?

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avalo Therapeutics' stock price today?

One share of AVTX stock can currently be purchased for approximately $0.14.

How much money does Avalo Therapeutics make?

Avalo Therapeutics (NASDAQ:AVTX) has a market capitalization of $2.84 million and generates $18.05 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

How can I contact Avalo Therapeutics?

Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The official website for the company is www.avalotx.com. The company can be reached via phone at (410) 522-8707 or via email at ir@cerecor.com.

This page (NASDAQ:AVTX) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -